{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"17"}],"title":"complete response rate, very good partial response/partial response rate"},{"measurements":[{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"19"}],"title":"Stable response or progression of disease"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"36"}],"units":"Participants"}],"description":"Overall response rate (ORR), complete response rate, very good partial response/partial response rate will be summarized using proportions and confidence intervals will be provided. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","groups":[{"description":"Romidepsin 8 mg/m\\^2/Lenalidomide 10 mg","id":"OG000","title":"Dose Level -1"},{"description":"Romidepsin 8 mg/m\\^2/Lenalidomide 15 mg","id":"OG001","title":"Dose Level 1"},{"description":"Romidepsin 8 mg/m\\^2/Lenalidomide 25 mg","id":"OG002","title":"Dose Level 2"},{"description":"Romidepsin 10 mg/m\\^2/Lenalidomide 25 mg","id":"OG003","title":"Dose Level 3"},{"description":"Romidepsin 14 mg/m\\^2/Lenalidomide 25 mg","id":"OG004","title":"Dose Level 4"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"No participants treated on Dose Level -1","reportingStatus":"POSTED","timeFrame":"1 year","title":"Assess the Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Participants"}